🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Abstract Submission Deadline for the #SITC Spring Scientific is Jan. 8, 2025! Cellular Therapy for Solid #Tumors, will include poster and encore presentation opportunities, and at least 15 oral abstract presentations opportunities. Submit an abstract: go.sitcancer.org/4fupoc0

🚨New paper alert! In collaboration with the @ND_BakerLab, we uncover the molecular mechanisms that enable TCR specificity for a PI3Ka public neoantigen over its wild-type counterpart. Memorial Sloan Kettering Cancer Center University of Notre Dame Parker Institute for Cancer Immunotherapy #Tcellpower #openaccess rdcu.be/d6W1n.

👀Tumor cells promotes TIL dysfunction through transfer of dysfunctional mitochondria👀 Fascinating new mechanism for tumor-induced T cell dysfunction in nature today. Interesting parallels to recent paper by the Gattinoni Lab. rdcu.be/d687T

Honored to have worked with this dream team to organize the Society for Immunotherapy of Cancer #SpringScientific on #CellularTherapies for #SolidTumors. Join us next month (March 12-14)! sitcancer.org/education/spri…

Coming soon! Society for Immunotherapy of Cancer Spring Scientific meeting on Solid Tumor Cell Therapy next month in beautiful 🌴San Diego🌴! Join us for many great sessions, including one dedicated to emerging TCR-based therapies. Jason Luke, MD, FACP Inaki Etxeberria Memorial Sloan Kettering Cancer Center The Netherlands Cancer Institute Parker Institute for Cancer Immunotherapy

Join us Society for Immunotherapy of Cancer Spring Scientific on #CellularTherapy for #SolidTumors in San Diego, March 12-14. Session preview: "Novel Targets for Solid Tumor Cell Therapies" featuring experts Drs. Heath Lab, Hideho Okada & Mark Yarmarkovich. Program and registration: sitcancer.org/education/spri…

Bravo Tal, the entire lab is so proud of you and your work🙌🧬🙌! Memorial Sloan Kettering Cancer Center MSK Department of Medicine

🚨Today in nature, we show that mRNA mis-splicing creates clonal public neoantigens in solid cancers. An amazing collaboration between UCSF Helen Diller Family Comprehensive Cancer Ctr and Memorial Sloan Kettering Cancer Center driven by Darwin Kwok and co-led by Hideho Okada, Joe Costello and Klebanoff_Lab. nature.com/articles/s4158…

True story: the privately held biotechnology company Colossal Bioscience (co-founded by George Church) created a novel mouse strain containing the shaggy-hair gene of an extinct Wooly Mammoth. These guys are pretty darn cute.

Newly elected #NASmember Steven A. Rosenberg of National Cancer Institute pioneered the first effective immunotherapies for patients with advanced cancer. Read more: ow.ly/e96k50VjnPj

Excited to represent Society for Immunotherapy of Cancer and join an amazing cadre of international IO investigators at EACR 5th Immuno-Oncology Conference in Barcelona 🇪🇸. I'll be discussing emerging insights into the role of CD4+ T cells in anti-tumor immunity to human solid cancers. Join us!

Bravo Mike V. Gormally, MD PhD 🙌! Memorial Sloan Kettering Cancer Center MSK Department of Medicine #Tcellpower

Klebanoff Lab's "Physician-Scientist Action Hero." Mad scientist playset sold separately. *Batteries not included. chatgpt.com/s/m_6801711d79….

🚨Today in Cell, we show that RNA splicing factor mutations in myeloid cancers generate splicing-derived public neoantigens targetable by #TCR tx. Amazing collaboration co-led by Abdel-Wahab Lab, Robert K. Bradley, and Klebanoff_Lab. #Tcellpower cell.com/cell/fulltext/…

Research fellow Mike V. Gormally, MD PhD will present results of a real-world analysis that evaluated HLA LOH frequencies & survival outcomes in cancer. Memorial Sloan Kettering Cancer Center AACR #AACR25 Learn more: bit.ly/44Ij39Y Session starts at 2:30 p.m. CT | Presentation at 3:05 p.m. CT

Join Session Chair and CRI Investigator Dr. Klebanoff Memorial Sloan Kettering Cancer Center at 10:15 AM today for #AACR's SY16 - Novel Classes of Human Cancer Rejection Antigens: Beyond Point Mutations, and hear from Dr. Okada UC San Francisco and Dr. Amigorena of Institut Curie. More: bit.ly/4jlEJgE

Bravo Mike V. Gormally, MD PhD 🙌🧬🥼!

🚨🧬Everything you wanted to know about actionable #neoantigens resulting from cancer mutations besides point mutations (*but were afraid to ask). Join us at 10:15 in 📍Room E351 - McCormick Lakeside Center (Level 3)! Memorial Sloan Kettering Cancer Center UCSF Helen Diller Family Comprehensive Cancer Ctr Institut Curie

MSK physician-scientist Klebanoff_Lab talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.

👉Today in The Lancet Oncology: phase I trial of #CISH KO #neoantigen-selected #TIL in GI cancers. Proud to have worked in collaboration with Emil Lou, MD, PhD, FACP, the Webber/Moriarity labs Masonic Cancer Center, University of Minnesota, and #IntimaBioscience from pre-clinical->IND->first-in-human. authors.elsevier.com/c/1l0Jr_XRRTs9…